Scholar Rock Holding Operating Income Growth & History (SRRK)
Scholar Rock Holding's operating income was −$384.6M for fiscal 2025.
View full Scholar Rock Holding company overviewScholar Rock Holding annual operating income history
| Fiscal year | Period ended | Operating income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$384.6M | −$132.6M | — |
| 2024 | 2024-12-31 | −$252.1M | −$80.8M | — |
| 2023 | 2023-12-31 | −$171.3M | −$36.9M | — |
| 2022 | 2022-12-31 | −$134.4M | −$4.4M | — |
| 2021 | 2021-12-31 | −$129.9M | −$43.0M | — |
| 2020 | 2020-12-31 | −$86.9M | −$32.3M | — |
| 2019 | 2019-12-31 | −$54.5M | −$3.9M | — |
| 2018 | 2018-12-31 | −$50.7M | −$25.7M | — |
| 2017 | 2017-12-31 | −$25.0M | — | — |
Scholar Rock Holding quarterly operating income
| Fiscal quarter | Period ended | Operating income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$108.9M | $3.2M | — |
| Q1 2026 | 2026-03-31 | −$102.0M | −$24.9M | — |
| Q4 2025 | 2025-12-31 | −$91.9M | −$22.5M | — |
| Q3 2025 | 2025-09-30 | −$103.5M | −$38.8M | — |
| Q2 2025 | 2025-06-30 | −$112.1M | −$52.6M | — |
| Q1 2025 | 2025-03-31 | −$77.1M | −$18.7M | — |
| Q4 2024 | 2024-12-31 | −$69.4M | −$21.3M | — |
| Q3 2024 | 2024-09-30 | −$64.8M | −$21.1M | — |
| Q2 2024 | 2024-06-30 | −$59.5M | −$20.4M | — |
| Q1 2024 | 2024-03-31 | −$58.4M | −$17.9M | — |
| Q4 2023 | 2023-12-31 | −$48.0M | −$7.6M | — |
| Q3 2023 | 2023-09-30 | −$43.7M | $190,000 | — |
| Q2 2023 | 2023-06-30 | −$39.1M | $4.1M | — |
| Q1 2023 | 2023-03-31 | −$40.5M | −$33.6M | — |
| Q4 2022 | 2022-12-31 | −$40.4M | −$5.1M | — |
| Q3 2022 | 2022-09-30 | −$43.9M | −$6.8M | — |
| Q2 2022 | 2022-06-30 | −$43.1M | −$12.9M | — |
| Q1 2022 | 2022-03-31 | −$6.9M | $20.3M | — |
| Q4 2021 | 2021-12-31 | −$35.4M | −$9.3M | — |
| Q3 2021 | 2021-09-30 | −$37.1M | −$13.5M | — |
| Q2 2021 | 2021-06-30 | −$30.3M | −$10.8M | — |
| Q1 2021 | 2021-03-31 | −$27.2M | −$9.5M | — |
| Q4 2020 | 2020-12-31 | −$26.1M | −$13.8M | — |
| Q3 2020 | 2020-09-30 | −$23.6M | −$6.5M | — |
| Q2 2020 | 2020-06-30 | −$19.5M | −$6.1M | — |
| Q1 2020 | 2020-03-31 | −$17.7M | −$6.0M | — |
| Q4 2019 | 2019-12-31 | −$12.3M | $3.2M | — |
| Q3 2019 | 2019-09-30 | −$17.1M | −$5.9M | — |
| Q2 2019 | 2019-06-30 | −$13.4M | $1.5M | — |
| Q1 2019 | 2019-03-31 | −$11.7M | −$2.7M | — |
| Q4 2018 | 2018-12-31 | −$15.6M | — | — |
| Q3 2018 | 2018-09-30 | −$11.2M | −$5.3M | — |
| Q2 2018 | 2018-06-30 | −$14.9M | −$9.0M | — |
| Q1 2018 | 2018-03-31 | −$9.0M | — | — |
| Q3 2017 | 2017-09-30 | −$5.9M | — | — |
| Q2 2017 | 2017-06-30 | −$5.9M | — | — |
Scholar Rock Holding operating income trends
Over the last five fiscal years, Scholar Rock Holding's operating income decreased from −$86.9M to −$384.6M, a change of −$297.8M. The latest reported quarter, Q2 2026, shows −$108.9M.
What operating income means
Operating income is the profit or loss a company generates from its core business after cost of revenue and operating expenses, but before non-operating items such as interest and income taxes.
SEC-reported operating income
TickerStat standardizes operating income reported in company SEC filings for aligned fiscal periods. It is not adjusted EBIT, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Scholar Rock Holding source filings ↗Community posts
Scholar Rock wins FDA approval for muscle-targeted SMA treatment
Scholar Rock ($SRRK) received FDA approval for ISEMBYLD, its apitegromab treatment for spinal muscular atrophy, in patients aged two and older receiving SMN2-targeted therapy. The company plans to begin shipping the medicine within days. Th ...